S epsis has become increasingly prevalent over the past several decades worldwide with an estimated current frequency of between 400,000 and 750,000 cases per year in North America (1) (2) (3) (4) . Approximately half of these patients develop shock and half of those, or approximately 100,000 to 250,000 per year in North America, will die of the disease (1) (2) (3) (4) (5) .
Sepsis is one of the most common causes of death in intensive care units in the United States (6, 7) . The rate of hospitalization for sepsis in the United States continues to increase (5, 7) . This potentially devastating clinical syndrome is thought to be mediated by a systemic inflammatory response to invasive infection (8 -10) . Coagulation abnormalities also seem to mediate the clinical syndrome of sepsis (11) . As the clinical syndrome progresses, the process results in circulatory collapse, respiratory failure, and progressive loss of vital organ function, producing the multiple organ dysfunction syndrome (1, 6) . Despite advances in antibiotic therapy, and general supportive care of critically ill adults, the mortality rates for sepsis have remained high and may be relatively unchanged over the last 25 yrs (1).
On average, about 75% of patients with clinically suspected severe sepsis have a documented microbial infection (6, 8, 9) . As high as 50% of all cases of sepsis are associated with a positive bacterial blood culture and about two-thirds of the documented infections are caused by Gram-negative bacteria (6, 8, 9) . Aside from antibiotic, surgical, and intensive care unit supportive care, no specific pharmacotherapy has been available for sepsis or its associated organ dysfunction until recently (11) .
Although the pathogenesis of septic shock is incompletely understood, bacterial products, particularly Gram-negative endotoxin and other bacterial components, seem to have a critical role in initiating and perpetuating a physiologic cascade in the setting of severe infection (8, 10) . As a result, adjunctive immunotherapy directed at these bacterial products, were the focus on encouraging early investigative efforts to treat sepsis (12, 13) . This led to the development of several monoclonal antibodies against endotoxin, which to date, have not shown acceptable efficacy in large prospective human trials (9, (13) (14) (15) (16) . Recent advances in molecular biology, immunology, and the clotting cascade have provided insight into the role of host mediators and cellular responses in severe infection. The possibility of an excessive inflammatory response has been raised (9, 17) . Several immune-modulating agents have been studied in an effort to influence the outcome of sepsis (10) . Tumor necrosis factor, bradykinin, and interleukin-1, in particular, have been the targets in several trials (18 -26) . However, until recently, these approaches have failed to produce definitive positive results in human trials using prospectively defined criteria. A recent large study looking at recombinant human actuated protein C in sepsis has been promising enough to result in Food and Drug Administration approval (11) .
Another unique potential approach to the treatment of sepsis would involve immunotherapy directed against the offending organism, but not specifically against endotoxin. The enterobacterial common antigen (ECA) is a specific glycophospholipid surface antigen shared by all members of the family Enterobacteriaceae (27) (28) (29) (30) . Organisms from that family are responsible for approximately 70% of proven Gram-negative infections (28, 31) . ECA is found in close association with endotoxin in the bacterial cell wall, in some circumstances bound to its core, but may be more antigenic than endotoxin (32) . ECA seems to have an identical structure in all species within the Enterobacteriaceae family, but is not present in other Gram-negative bacteria such as Pseudomonas (28) . The protective value of antibodies to ECA has been demonstrated with in vitro and in vivo models of both passive and active immunity but have given conflicting results as to mechanism of action (28, 33, 34) . This protection seems to require complement and likely involves opsonization and an increased rate of phagocytic clearance of bacteria (28) . Although the potential for therapeutic use of anti-ECA antibodies in humans has been theorized, such agents have never been investigated in a large randomized clinical trial.
MAB-T88 is a human monoclonal immunoglobulin M antibody, containing a small murine J chain component. Although MAB-T88 was selected based on the apparent specificity for lipo-polyarharive (core-lipid A region), in vitro, MAB-T88 was later demonstrated to have a high binding affinity for ECA (35) . Preclinical studies have shown that MAB-T88 enhances opsonization, complement fixation, and in vivo clearance of ECAcontaining organisms (35) . Phase I/II trials demonstrated an acceptable safety profile in patients with and without sepsis (36, 37) . In this randomized, multicenter, double-blinded comparative trial, we evaluated the efficacy of a single dose of MAB-T88 in patients with Gram-negative sepsis, and specifically those infected with an organism of the family Enterobacteriaceae.
PATIENTS AND METHODS
A randomized, double-blinded, placebocontrolled, multicenter study was performed to evaluate the safety and efficacy of MAB-T88 antibody in the treatment of Enterobacteriaceae sepsis. The primary end point for efficacy was a 28-day all-cause mortality reduction in patients receiving MAB-T88 compared with placebo. The study was performed in 33 U.S. medical centers with the goal of enrolling a total of 850 patients and was designed for a study power of Ͼ0.9 to detect a 15% absolute decrease in all-cause mortality. Individual institutional review board approval was obtained at each center and informed consent was obtained for each study patient before study participation.
Patient Selection. Patients with sepsis from presumed or proven Gram-negative infection were eligible for study participation. Criteria for presumed or proven Gramnegative infection included a high clinical suspicion coupled with confirmatory Gramnegative stain (e.g., sputum or urine) or culture results within 72 hrs before drug infusion. The suspicion of an intra-abdominal infection did not require predrug infusion culture or Gram-negative stain results.
Patients were required to demonstrate evidence of a systemic inflammatory process characterized within 24 hrs of infusion by core temperature alteration (Յ35.5°C or Ն 38.3°C), tachycardia (Ն90 beats/min in the absence of ␤-adrenergic blockade), tachypnea (Ն20 breaths/min or requirement for mechanical ventilation), and evidence of hypotension or dysfunction of two end-organs. Hypotension was defined as one of the following: supine systolic blood pressure Յ90 mm Hg; acute decrease in systolic blood pressure Ն40 mm Hg despite adequate fluid administration and in the absence of antihypertensive agents; or the requirement for vasopressors (e.g., dopamine at Ͼ3 g/kg/min) to maintain systolic blood pressure Ն90 mm Hg. Evidence of endorgan dysfunction was defined as: metabolic acidosis attributed to sepsis (pH Յ7.30 or base deficit Ն5 or plasma lactate greater than upper limits of normal); hypoxia (PaO 2 Յ65 mm Hg or PaO 2 /FIO 2 ratio Ͻ300 or SaO 2 Ͻ90%) without overt preexisting cardiac or pulmonary disease; acute oliguria (Ͻ0.5 mL/kg/hr) despite adequate volume loading; acute unexplained thrombocytopenia (Ͻ75,000 platelets/mL or 50% decrease from baseline) and hypofibrinogenemia (Ͻ250 mg/dL); or hyperdynamic cardiovascular response (cardiac index Ͼ4.0 L/min/m 2 with systemic vascular resistance index Ͻ1400 dyne/sec/m 2 /cm Ϫ5 or cardiac output Ͼ7.0 L/min with systemic vascular resistance Ͻ800 dyne/sec/cm Ϫ5 ). Patients were excluded from the study if one of the following was present: age Ͻ18 yrs; pregnancy; weight Ͼ150 kg; presence of a clear and irreversible disease other than sepsis which was expected to be rapidly fatal; participation in another investigational drug study; lung transplant; burns; previous monoclonal antibody therapy for sepsis; presence of cardiogenic shock; or uncontrolled hemorrhage. Immunocompromise was not considered a contraindication to study participation.
Therapeutic Intervention. Patients were randomly assigned within study centers to receive either 300 mg of MAB-T88 in albumin (Chiron Corporation, Emeryville, CA), intravenously as a single dose or a single dose of human serum albumin in an equivalent volume. Routine care of patients was continued with antibiotic, surgery, and fluid volume administration determined by the treating physician without interference by the study protocol.
Clinical and Laboratory Evaluation. Preadmission screening tests and evaluations were used to determine the eligibility of each candidate relative to the inclusion and exclusion criteria. Periodic clinical and laboratory determinations were performed throughout the length of the study. Vital signs were recorded multiple times an hour during the initial several hours, every 6 to 12 hrs through day 3, and again at days 8, 14, and 28, or daily while still in the intensive care unit. Physical examinations and the results of laboratory tests including electrolytes, liver function tests, serum urea nitrogen, creatinine, complete blood cell count, prothrombin time, partial thromboplastin time, uric acid, glucose, calcium, magnesium, phosphorous, total protein, fibrinogen, lactate, and urinalysis were recorded before treatment and on days 2, 3, 8, 14, and 28. Total hemolytic complement was measured before treatment and again at 30 mins and 6 hrs. C-reactive protein was measured before treatment and again on day 2.
The severity of illness at presentation was assessed by calculation of an Acute Physiology and Chronic Health Evaluation II score, as well as the presence and severity of underlying disease. Assessments of organ dysfunctions, including shock, disseminated intravascular coagulation, acute respiratory distress syndrome, and acute renal failure were made at entry and serially during the hospital course as outlined for the examinations.
In vitro susceptibility of microorganisms isolated was recorded both during the study period, and for the interval of 3 days before entry. Antibiotic therapy administered during these time frames was also recorded, in addition to other medications administered to the patient within the entire 28-day study period, or until death. Where available, data regarding results of arterial blood gas measurements and hemodynamic monitoring (central venous pressure and pulmonary artery catheter pressure measurements) were also recorded.
Evaluation. The primary analysis group (PAG) for efficacy consisted of those patients with a documented infection with Enterobacteriaceae before study entry. This determination was made based on culture results obtained within 72 hrs before study drug administration. The presence of any prestudy Enterobacteriaceae organism in a culture from a source considered "adequate" by defined criteria was sufficient for the patient to be included in the PAG. Two secondary analysis groups were identified to include patients with Enterobacteriaceae bacteremia, and all treated patients (ATP). Patients were evaluated for demographic variables, sites of infection, adequacy of antibiotics at the time of study drug administration, adequacy of surgical or other interventions for infection source control, and the presence of acute or chronic organ dysfunction. Four patient characteristics were designated primary covariates before breaking the study blind and were used in the statistical model to assess efficacy. These included the Acute Physiology and Chronic Health Evaluation II score, presence of shock, age, and an isolated urinary tract infection as the primary site. These variables were selected as having potential for significant influence on the primary end point and were also used to control for potential imbalance between study groups. Shock was defined as the presence of hypotension as described in the entry criteria. "Adequate fluid administration" was determined by the investigators at each site but generally exceeded 500 mL of saline. Covariates were determined based on information present at the time of study drug administration. The PAG, secondary analysis groups, and primary covariates were all prospectively determined.
Before unblinding, a four-member Clinical Evaluation Committee reviewed all patients to determine their assignment to the appropriate evaluation group, underlying cause of sepsis, presence of shock, causative organism(s), site of infection, adequacy of antibiotic therapy, and adequacy of surgical therapy. The committee prospectively defined criteria for acute and chronic organ failure, adequacy of culture source, and adequacy of antibiotic and surgical therapy. Adequate antibiotic therapy was defined as the prestudy administration of any antibiotic or combinations of antibiotics to which all microorganisms that met criteria for culture source adequacy by defined criteria, were sensitive. Adequate surgical therapy was defined as the timely and appropriate performance of any procedure directed at eradicating the source of infection. The Clinical Evaluation Committee and supporting sponsor personnel remained blinded at all times to treatment group assignment.
Statistical Analysis. The primary outcome for defining treatment efficacy was all-cause mortality within the first 28 days in the PAG for all patients who received complete study drug dosing. Time to death through 28 days was analyzed using the proportional hazards model with the distribution-free approach of Cox (38) . Significance was set at a full twosided, ␣ ϭ 0.05 level, using the Wald chisquare statistic. No interim analyses were conducted.
From prior similar trials, the mortality of patients meeting the entry criteria with sepsis was projected to be 40% at 28 days (12) . It was estimated that Ն50% of enrolled patients would meet the criteria defined for the PAG. The trial was designed to detect a relative mortality difference of 37.5% (i.e., a 15% absolute reduction of mortality from 40% to 25%) in the treated group. With those projections, the trial had a power of 0.91 to detect the proposed 37.5% relative reduction in mortality, and a power of 0.99 to detect a 50% reduction in mortality in the PAG (39) .
Analysis of safety used the same end point and statistical methods as for the analysis of efficacy, but was applied to all patients who received any study drug (even if incomplete) and did not have an ECA-related infection (i.e., the complement of the PAG group). MAB-T88 was considered to have an adverse effect in this group if a one-sided p value in the Cox proportional hazards model, adjusted for the four primary covariates were Ͻ.05. Other analyses of safety included descriptive summaries comparing MAB-T88 with placebo. Clinical adverse events, changes in vital signs, and changes in laboratory values were examined. Secondary analyses included comparison of the unadjusted Kaplan-Meier survival curves using the log-rank test (40, 41) .
RESULTS
A total of 826 patients were enrolled in the clinical trial and randomized to treatment. Of these, 411 patients received MAB-T88 and 415 received placebo treatment. A total of three patients (all randomized to MAB-T88) did not receive a complete infusion of study drug. As prospectively defined in the protocol, these patients were excluded from the efficacy analyses but included in safety analyses. One patient was lost to follow-up after being discharged from the hospital on study day 15. This patient was included in all analyses and considered "alive" for the landmark mortality analysis, but censored at day 15 in the analysis of survival time.
Baseline demographic characteristics by treatment groups are summarized in Table  1 . The mean age for all patients enrolled in the study was 57.2 yrs with a range of 18 to 94 yrs. The mean Acute Physiology and Chronic Health Evaluation II score was 26.8 Ϯ 8.4 (mean Ϯ SD) for both treatment groups. There was a statistically significant difference between MAB-T88 and placebo groups in the number of patients who entered the study with shock based on the protocol definition (MAB-T88: 80.3% vs. placebo: 85.8%, p ϭ .035). However, the number of patients requiring vasopressors at the time of study drug administration was equal between the two groups (49.2% vs. 48.4%, p ϭ .832). There was a trend toward more chronic renal failure in the MAB-T88-treated patients in both the ATP (5.6% vs. 3.1%, p ϭ .083) and the PAG (4.4% vs. 1.3%, p ϭ .051) groups. There were no differences between the MAB-T88-and placebo-treated patients with regard to other baseline demographic characteristics, underlying conditions, severity of illness, or adequacy of antibiotic or surgical treatment.
The primary focus on infection and organisms isolated from enrolled patients are summarized in Table 2 . Overall, 20.5% of patients had a urinary tract source for their sepsis and 45.6% of patients had positive blood cultures. These percentages were higher in the documented ECA infection study group, as might be expected. Overall, 19.3% of patients had no documented primary site of infection. Most of these were surgical patients in whom an intra-abdominal infection was diagnosed clinically, but no cultures were obtained, or were not positive, before study drug administration. The ATP group had a higher frequency of A total of 315 patients met entry criteria but did not culture a confirmatory ECA organism. These patients were assigned to the ATP group. A total of 55 patients did not meet the entry criteria stated in the protocol. These patients were also assigned to the ATP group. Thirty-six patients did not meet the criteria because of lack of evidence of Gramnegative infection. Nineteen patients did not meet the physiologic entry criteria. Three enrolled patients were in violation of the exclusion criteria and 21 patients received other therapies that were excluded while the patient was on the study. All such patients who deviated from the protocol were included in the analyses for safety and efficacy, but had no impact on the study results.
Efficacy Analysis. Mortality results are summarized in Table 3 . This includes the Cox proportional hazards analysis, which considers time to death within the first 28 days and adjusts for the four primary covariates.
The PAG, which is the subset of patients with documented ECA infections, was prospectively identified as the group most likely to show benefit. As shown in Table 3 , there was no significant difference in mortality within the first 28 days between the MAB-T88 and placebo groups in the PAG (34.2% vs. 30.8%, p ϭ .44). The Kaplan-Meier survival curve is shown in Figure 1 . The calculated relative risk is 1.08, slightly favoring the placebo patients, but with a wide 95% confidence interval (0.78 to 1.49).
Among ATP, there was no significant difference in mortality within the first 28 days between those treated with MAB-T88 Figure 2 shows the Kaplan-Meier survival curves for ATP. Although not statistically significant, the curves also slightly favor the placebo group after day 12.
Analyses of prospectively identified subsets found contradictory results. In the 217 patients with Enterobacteriaceae bacteremia, the use of MAB-T88 was associated with a slightly decreased mortality (30.8% vs. 35.5%, p ϭ .47). The relative risk after adjustment for the primary covariates was 0.77 (p ϭ .28), with wide 95% confidence intervals (0.48 to 1.24).
The other subgroup of the PAG are those 238 patients with an ECA infection but without bacteremia. In contrast to the Enterobacteriaceae bacteremia group, the results for patients with ECA without bacteremia were in the opposite direction and favored placebo-treated patients. This subgroup showed lower mortality at 28 days in those patients receiving placebo (26.5%) vs. those treated with MAB-T88 (37.2%, p ϭ .08), resulting in a relative risk of 1.39 favoring placebo (95% confidence interval of 0.88 to 2.21, p ϭ .16).
Safety Analysis. A primary safety group was defined in the protocol as all patients not in the PAG. Because patients in this group had no documented ECA infection, MAB-T88 was not expected to have significant therapeutic effect. Therefore, it was identified prospectively as the group in which any excess mortality seen with MAB-T88 treatment may reflect an adverse effect from drug toxicity. Twentyeight-day landmark, all-cause mortality in this group was 40.7% for MAB-T88-treated patients, versus 37.8% for those who received placebo (p ϭ .57). Using the Cox survival analysis for the first 28 days, which adjusts for the primary covariates, the relative risk was 1.16 favoring placebo with a 95% confidence interval of 0.83 to 1.61 (p ϭ .38, two-sided).
Three patients did not receive the entire dose of study drug. All were treated with MAB-T88 and all required interruption of the infusion because of acute development of severe hypotension associated with a rash or flushing. In each case, the principal investigator thought that this reaction was "probably related" to the study material. Each patient was acutely resuscitated from the event, although one died later during the hospitalization.
Overall, a greater number of adverse events were reported in those receiving MAB-T88 (28%) compared with those receiving placebo (23%) (p ϭ .094, chisquare). In one subgroup, those with ECA bacteremia, the frequency of all reported adverse events was significantly higher in the MAB-T88 (30%) vs. placebo (18%) treated patients (p ϭ .047). Although the majority of adverse events reported in each group related to the cardiovascular system, there were no significant differences between the two groups in this category. No differences were noted in adverse events for any of the other organspecific systems analyzed for the PAG or ATP groups. On secondary analyses, the only statistically significant difference was noted in the ECA nonbacteremia group in which adverse respiratory events were more common in the MAB-T88-treated patients (17 vs. 5, p ϭ .009). Significant adverse events thought to be "possibly or probably" treatment related, by the investigators, are summarized in Table 4 . These were more common in MAB-T88-treated patients (13 vs. 7, p ϭ .168) but did not reach significance in any individual category. There were no statistically or clinically significant differences in vital-sign data or findings of routine laboratory studies with MAB-T88 treatment. Additionally, no significant differences were noted in measurement of total hemolytic complement or in C- Figure 1 . Kaplan-Meier survival curves in all treated patients (n ϭ 823). Comparison of the survival curves using the log-rank test showed a p value of .425. reactive protein compared with the placebo-treated patients.
DISCUSSION
Many thousands of patients have now been included in recent clinical trials evaluating new interventional agents for sepsis (11-15, 18 -25, 27) . Each of these trials has attempted to intervene by either binding an initiator of the sepsis cascade, such as endotoxin (12) (13) (14) (15) (16) , or by modulating one of the cascade mediators such as bradykinin (24), interleukin-1 (25, 26) , or tumor necrosis factor-␣ (18 -23) . Until the most recent large phase III clinical trials with an antibody to tumor necrosis factor and with activated protein C (11, 42) , no significant outcome changes have been noted (43, 44) .
MAB-T88 is a novel monoclonal antibody that demonstrated marked affinity for a surface antigen (ECA) found on Gram-negative bacteria of the family Enterobacteriaceae (32) (33) (34) . As such, this agent differs significantly from those used in other sepsis clinical trials, which focused on either initiators or mediators of the physiologic cascade. Based on in vitro findings (35) , it was theorized that MAB-T88 would enhance opsonization, complement fixation and effective clearance of infecting organisms containing ECA. However, the results of this study failed to demonstrate reduced mortality within the first 28 days in sepsis patients treated with a single dose of MAB-T88, regardless of the presence of documented Enterobacteriaceae infection. These results were negative for those with focal infections, as well as for those with bacteremia.
Previous negative sepsis trials have been criticized for multiple design problems, including inadequate power to detect a meaningful reduction in mortality (43, 44) . In this trial, it was estimated, a priori, that 425 patients would meet the criteria for the PAG and this would provide Ͼ90% power to detect a 37.5% relative reduction in mortality in patients treated with MAB-T88. In fact, 456 patients met the criteria for the PAG. It is unlikely that a large clinically significant beneficial drug effect was missed because of an inadequate sample size. Although this was a relatively large trial, which was sufficiently powered to detect its prospective intended difference in mortality, it still could be argued that the goal of 37.5% relative difference was too large. Perhaps the 6% to 20% relative difference in mortality reported in recent positive sepsis trials (11, 42) would be more likely to have been seen and should have been the target. This would have required more power in the study and a much larger trial. However, because no trend in mortality benefit was seen at all in either the PAG or the ATP analysis, it seems unlikely that the trial had a significant type II error. A concern in this study is that the ATP analysis actually showed a small numerical increase in all-cause 28-day mortality in patients treated with MAB-T88 (37% vs. 34%, p ϭ .36). This was found in patients with or without documented ECA infections except for the subgroup with the documented ECA bacteremia. This also makes it unlikely that a larger trial, using this dose regimen, could find a positive therapeutic effect in the PAG used here. This does not preclude potential efficacy of MAB-T88 using different dosing regimens or entry criteria.
In general, the study groups were well balanced. Where imbalances existed, they tended to favor the placebo group, except for the presence of shock, which was more common in that group. Although these differences were not statistically significant, at study entry, there was a trend toward more MAB-T88 patients requiring vasopressors, having underlying chronic renal failure, or having developed disseminated intravascular coagulation by the time of enrollment. In addition, slightly more patients in the MAB-T88-treated group received inadequate antibiotic or surgical therapy. In combination, these factors may have contributed to the trend toward increased mortality in the study group.
Overall, adverse events were reported more frequently in the MAB-T88 group compared with the placebo group, but this did not reach statistical significance. Although the numbers are small, there were more skin rashes (4 vs. 1) and development of hypotension (7 vs. 4) associated with receiving MAB-T88. Most importantly, the three study patients who required discontinuation of study infusion for severe hypotension were receiving MAB-T88. Taken in conjunction with the overall mortality data, a trend toward a small adverse treatment effect associated with MAB-T88 cannot be excluded.
A unique aspect of this study protocol, relative to other clinical trials in sepsis, was the requirement for specific evidence of Gram-negative infection before enrollment. This requirement at study entry did select patients at slightly higher risk for a Gram-negative infection (589 of 826, 72%), but did not improve the enrollment of patients with Gram-negative bacteremia (281of 826, 34%) compared with other clinical sepsis trials targeting Gram-negative infection with a similar frequency of 28% to 41% rate of Gramnegative bacteremia (12) (13) (14) (15) (16) . One concern is that the requirement for microbiological evidence of infection before study entry prolonged the time from onset of actual sepsis (based on physiologic criteria) to treatment with study drug. Sixty-seven percent of the patients in this trial were treated Ͼ12 hrs after meeting all of the physiologic entry criteria. This compares to only 49% of patients treated Ͼ12 hrs after presumed onset in another phase III sepsis trial focusing on Gramnegative organisms using otherwise similar entry criteria for presumed sepsis (12) . Interestingly, in the current trial, patients treated within 0 to 6 hrs and Ͼ24 hrs after the physiologic onset of sepsis had higher mortality rates (41%) than those patients treated within 6 to 24 hrs from the onset of sepsis (30.5%). This is similar to data reported in the initial HA-1A phase III clinical trial (12) . Therefore, it is difficult to determine whether a delay in enrollment and study treatment would have a significant impact on survival in this population.
Despite the fact that this trial had a requirement for specific evidence of Gram-negative infection before enrollment, nearly 20% or 159 of the enrolled patients had no actual documented site of infection. This compares to other multicenter sepsis studies that have found as high as 30% of severe sepsis cases have no documentable infection (11-16, 18 -26) . In this study, 36 of 159 patients were entered with a presumed abdominal source for which no culture was ever obtained, or the culture was negative. Another 87 patients were entered based on adequate Gram stains with cultures that were subsequently negative. Within the microbiological entry criteria, the "presumed abdominal source" was found to be the least specific or objective. Some patients enrolled using these criteria never underwent surgery or other interventional therapies and never had intraabdominal cultures taken. However, the number of patients enrolled in this trial with a presumed abdominal source for their sepsis (24%) is less than the 32% reported in a large prospective sepsis survey study (5) . If future trials for Gramnegative sepsis use a similar approach to the entry criteria, this may be an important area to address.
The entry criteria used in this trial do not exactly match the most recent consensus definition of the systemic inflammatory response syndrome with infection (6, 9) . The study criteria were modeled on the formal definition of "sepsis syndrome" used in other sepsis trials at the time this study was initiated (12) . It should be noted that these criteria are not substantially different from the current definitions of severe sepsis and septic shock using the systemic inflammatory response syndrome criteria (9) and that there are no prospective studies demonstrating that these subtle differences would substantially change the study population.
In summary, MAB-T88, a novel human monoclonal antibody directed against the Enterobacteriaceae common antigen, was not found to be effective in reducing the mortality of sepsis associated with Enterobacteriaceae infection. A slight increase in reported adverse events was associated with the administration of MAB-T88.
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